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Abstract
Background: It is generally accepted that emphysematous lungs are characterized by an increase
in the numbers of neutrophils, macrophages, and CD8+ T lymphocytes, the lasts having increased
cytotoxic activity. Because systemic inflammation is also a component of emphysema, we
hypothesize that peripheral CD8+ T lymphocytes of emphysematous smokers who show evidence
of systemic inflammation will have higher expression of cytotoxic molecules.
Methods: We assessed parameters of systemic inflammation in normal individuals (smokers or
non-smokers) and in emphysematous subjects with an active smoking history by measuring serum
interleukine-6, C-reactive protein, and tumor necrosis factor. Expression of perforin, granzyme B,
and FasL protein by CD8+ T lymphocytes, CD4+ T lymphocytes, and natural killer cells were
assessed by flow cytometry while perforin, granzyme B, and FasL mRNA expression were
measured on purified systemic CD8+ T lymphocytes by real-time PCR.
Results: Emphysematous smokers had higher levels of serum interleukine-6 than normal subjects.
Even with the presence of systemic inflammation in emphysematous smokers, the percentage of
peripheral CD8+ T lymphocytes, CD4+ T lymphocytes, and NK cells expressing perforin and
granzyme B protein was not different between the three groups.
Conclusion:  Despite evidence of systemic inflammation, peripheral T lymphocytes of
emphysematous smokers did not show higher levels of cytotoxic markers, suggesting that increase
of activated T lymphocytes in the emphysematous lung may be due to either activation in the lung
or specific peripheral recruitment.
Background
Emphysema is a major component of chronic obstructive
pulmonary disease (COPD) which is essentially induced
by cigarette smoking or exposure to other noxious gases.
It is characterized by an inflammation-mediated destruc-
tion of the lung parenchyma which leads to distal air
space enlargement and non-fully reversible airflow
obstruction [1]. Neutrophils, macrophages, and T lym-
phocytes are thought to play an important role in this
inflammatory process [2].
Because the presence of T lymphocytes in smoker's lungs
has been found to correlate with emphysema [3], their
role in the pathogenesis of the disease has been studied
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extensively. In emphysematous subjects, the number of
CD8+ T lymphocytes is increased in central [4] and periph-
eral airways [5-7], leading to a decrease of the CD4/CD8
ratio [4,5,7]. Majo et al. [5] also showed that there was a
correlation between the presence of CD8+ T lymphocytes
in the lung parenchyma of smokers and their smoking
history as well as the apoptotic index of their alveolar
cells. Chrysofakis et al. [8] were able to document that per-
forin expression, a cytotoxic and activation marker, and
cytotoxic activity of CD8+ T lymphocytes in the sputum of
COPD smokers were higher than in smokers without
COPD. All these data suggest that CD8+ T lymphocytes
may have an important role in the pathogenesis of
emphysema. However, emphysema's damages are not
confined to the lung. Indeed, important systemic effects
such as muscle wasting and cachexia are also part of the
disease [9,10].
Although several authors have demonstrated the impor-
tance of lung T lymphocytes in emphysema, few studies
have described their state of activation and their cytotoxic
potential in the peripheral blood. Perforin, granzyme B,
and FasL are cytotoxic molecules used by CD8+ T lym-
phocytes and natural killer (NK) cells to induce apoptosis
[11]. Constitutively expressed by NK cells, perforin,
granzyme B, and FasL expression is induced upon activa-
tion by antigen presenting cells, such as dendritic cells, in
CD8+ T lymphocytes [11]. Because increased expression
of perforin and granzyme B by peripheral blood CD8+ T
lymphocytes has been reported in other chronic diseases
such as asthma [12] and systemic lupus erythematosus
[13], overexpression of cytotoxic molecules by systemic
CD8+ T lymphocytes or other types of lymphocytes may
also lead to non-specific systemic damages in the lungs of
emphysematous subjects. In the current study, we postu-
lated that systemic CD8+ T lymphocytes of emphysema-
tous smokers with evidence of systemic inflammation will
show higher expression of cytotoxic and activation mark-
ers such as perforin, granzyme B, and FasL than that of
subjects with normal lung function. To test this hypothe-
sis, we measured serum interleukine-6 (IL-6), tumor-
necrosis factor (TNF), and C-reactive protein (CRP) in
smokers with emphysema, smokers without emphysema,
and in non smokers with normal lung function. Expres-
sion of perforin, granzyme B, and FasL protein by systemic
T lymphocytes and NK cells was compared between the
three groups.
The results show that despite evidence of low-grade sys-
temic inflammation in emphysematous smokers, the
peripheral T lymphocytes of those subjects do not express
higher levels of perforin, granzyme B, and FasL, suggesting
that the increase of activated T lymphocytes in the lung of
emphysematous subjects may be due to either local intra
pulmonary activation or to specific recruitment.
Methods
Subjects
Twenty-nine subjects matched for age and sex were
included in the study: nine were active smokers with evi-
dence of emphysema and airflow limitation defined
according to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) [1] (FEV1 < 80% predicted value,
FEV1/FVC < 70% predicted value, and reversibility ≤ 12%
and 200 ml after salbutamol inhalation), 10 were smokers
with normal lung function, and 10 were non-smokers
with normal lung function. In subjects with airflow limi-
tation, the presence of emphysema was further confirmed
by a radiologist following CT scanning analyses and a dif-
fusion capacity (DLCO) < 80% predicted value for man
and < 70% predicted value for women. Subjects were
excluded from the study if they have a history of cancer in
the past five years, active liver, heart or kidney disease, dia-
betes or any other non emphysematous pulmonary con-
dition. In addition, all emphysematous subjects had to
have a negative prick test for common allergens and they
had been free of disease exacerbation within the previous
3 months. Two subjects were taking inhaled steroids but
none had received oral steroids or antibiotics for at least
four weeks before the study. The study was approved by
the Hospital Research Ethic Committee and all subjects
gave a written consent.
Serum IL-6, TNF, and CRP quantification
Serum TNF and IL-6 levels were measured with the Quan-
tikine HS human TNF immunoassay and the Quantikine
HS human IL-6 immunoassay (R&D Systems Inc.; Minne-
apolis, MN) according to the manufacturer's instructions.
Serum CRP levels were measured by a high sensitivity
nephelometer immunoassay using Dabe Behring BN
Prospec instrumentation (Dabe Behring, Deerfield, IL,
USA).
Peripheral blood mononuclear cells isolation and CD8+ T 
lymphocytes purification
For each subject, approximately 150 ml of blood was
drawn on K3-EDTA in BD Vacutainer (BD Biosciences;
Mississauga, ON, Canada) and processed as shown in Fig-
ure 1. Five milliliters of blood was used for automatic dif-
ferential analysis of blood cells, another 20 milliliters was
centrifuged at 2000 rpm for 10 min, the supernatant being
collected and kept at -80°C for serum IL-6, TNF, and CRP
quantification, and the remaining was used for peripheral
blood mononuclear cells (PBMC) isolation using Ficoll-
Paque Plus density gradient (Amersham Biosciences; Pis-
cataway, NJ) according to the manufacturer's instructions.
A fraction of the PBMC was directly used for flow cytom-
etry analysis. To deplete NK cells (CD16+) that are faintly
CD8+, the remaining PBMC were labeled with mouse
anti-human CD16 conjugated to magnetic beads
(Miltenyi Biotec Inc.; Auburn, CA) and CD16- cells wereRespiratory Research 2007, 8:62 http://respiratory-research.com/content/8/1/62
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negatively selected. Some of these CD16- cells were then
used for flow cytometry analysis while the remaining cells
were labeled with mouse anti-human CD8 conjugated to
magnetic beads (Miltenyi Biotec Inc.). CD8+  T lym-
phocytes were positively selected with a purity greater
than 90% as documented by flow cytometry (CD3+/CD8+
cells) (data not shown). Total RNA was extracted from
CD8+/CD16-  T lymphocytes. Analyses were done to
ensure that the magnetic cells sorting (MACS) and bind-
ing of CD8 antigen did not activate the CD8+ T lym-
phocytes: indeed, the percentage of perforin+/CD8+ and
granzyme B+/CD8+ cells was determined before CD8+ cells
selection. Following the positive selection, the resulting
CD8+ cells were cultured at 37°C 5%CO2 in RPMI 1640
without serum for up to 24 hours. After that period of
time, the percentage of perforin+/CD8+ and granzyme B+/
CD8+ cells was determined. No modulation in perforin
nor granzyme B protein expression was observed either
before and after the CD8 selection (data not shown).
Double labeling of T lymphocyte subsets and flow 
cytometry analyses
The following mouse anti-human monoclonal antibodies
were used to label PBMC and/or CD16- cells: phycoeryth-
rin-cyanine (PE-Cy5)-conjugated anti-CD3 (clone
HIT3a)(T lymphocytes), fluorescein isothiocyanate
(FITC)-conjugated anti-CD3 (clone HIT3a)(T lym-
phocytes), PE-Cy5-conjugated anti-CD8 (clone
HIT8a)(CD8+ T lymphocytes), PE-Cy5-conjugated anti-
CD4 (clone RPA-T4)(CD4+ T lymphocytes), phycoeryth-
rin (PE)-conjugated anti-CD56 (clone B159)(Natural
Killer cells), FITC-conjugated anti-perforin (clone δG9),
FITC-conjugated anti-granzyme B (clone GB11), and
Alexafluor 488-conjugated anti-FasL (clone NOK-1) (BD
Biosciences). The appropriate conjugated mouse isotype
controls were used in parallel (BD Biosciences).
To label surface antigens (CD3, CD8, CD4, CD56, and
FasL), 0.5 × 106 cells in phosphate buffered saline solution
(PBS) supplemented with 1% bovine serum albumine
(BSA) (Sigma-Aldrich Canada Ltd; Oakville, ON, Canada)
were incubated with appropriate antibodies or isotype
controls for 40 min on ice and protected from light. For
intracellular labeling of perforin or granzyme B, cells were
further permeabilized using Cytofix/Cytoperm solution
(BD Biosciences) for 20 min on ice and protected from
light. Cells were then washed with PBS-BSA 1% contain-
ing 0.1% of saponin (Sigma-Aldrich Canada Ltd) and
then incubated with the appropriate antibody or isotype
control 40 min on ice and protected from light. Cells were
finally washed with PBS-BSA 1%-saponin 0.1% and
immediately analyzed by flow cytometry.
Blood processing protocol Figure 1
Blood processing protocol.Respiratory Research 2007, 8:62 http://respiratory-research.com/content/8/1/62
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The labeled cells were analyzed on a Coulter EPICS XL-
MCL flow cytometer (Beckman-Coulter; Mississauga, ON,
Canada) with the EXPO 32 APC XL 4 Color program
(Beckman-Coulter). The lymphocytes were tightly gated
using complexity (side-light scatter) and volume (for-
ward-light scatter) parameters. The percentages of per-
forin, granzyme B, or FasL positive cells for each
population (CD3+, CD8+, CD4+ or CD56+) and the CD4/
CD8 ratio were evaluated by two colors analysis. At least
105 cells were analyzed in each session.
Real-time PCR
After magnetic cell sorting of peripheral blood CD8+ T
lymphocytes (CD16-/CD8+), total RNA was extracted
using RNeasy mini kit (Qiagen Inc.; Mississauga, ON,
Canada) according to the manufacturer's instructions. To
eliminate DNA contamination, extracted RNA was then
treated with RQ1 DNase (Promega Inc.; Ottawa, ON,
Canada) for 30 min at 37°C. Resulting RNA was washed
and concentrated in 37 µl of water using Microcon 100 fil-
tration column (Millipore; Billerca, MA, USA) and quan-
tified by spectrophotometry using GeneQuant pro RNA/
DNA Calculator (Biochrom Ltd; Cambridge, United King-
dom). Total RNA (500 ng) was reversed transcribed with
Omniscript Reverse Transcriptase (Qiagen Inc.) according
to the manufacturer's specification and using random
octamers. Resulting cDNA (final volume of 20 µl) was
kept at -80°C until further utilization.
Real-time PCR analyses were performed on a DNA Engine
Opticon 2 System (MJ Research; Reno, NV) with the
QuantiTect SYBR Green PCR Kit (Qiagen Inc.) according
to the manufacturer's specification. Primers sequences are
shown in Table 1 and were designed according to Lyon et
al. [14] (18S rRNA, used as housekeeping gene [15]) and
Wang and Seed [16] (perforin, granzyme B, and FasL).
PCR efficiency was confirmed for all genes to ensure
equivalent amplification rates when compared to 18S
rRNA. For each PCR reaction, 1 µl of the 1/100 dilution of
the cDNA stock was used for perforin, granzyme B, and
FasL analyses, and 1 µl of the 1/1000 dilution was used for
18S rRNA analysis. The PCR conditions were 94°C for 15
min, then 35 cycles at 94°C for 15 sec, 30 sec at specific
annealing temperature (see Table 1) and 72°C for 30 sec.
The method used to quantify the variation of expression
for perforin, granzyme B and FasL mRNA was the 2∆∆Ct
method [17]. Based on the 18S rRNA crossing threshold
(Ct), the ∆Ct of each gene was determined for each sub-
ject. Then, for each group of subjects, the mean expression
of each gene was compared to the normal non-smoker
group who represents the baseline expression.
Data analyses
Data are expressed as mean ± standard error (SEM). The
three groups were compared with the analysis of variance
(ANOVA) followed, if p < 0.05, by a post hoc Fisher's prob-
able least-squares difference (PLSD) test. Smoking history
of smokers with and without emphysema was compared
with an unpaired Student's T test (significantly different if
p < 0.05).
Results
Clinical findings
The characteristics of subjects are presented in Table 2.
The mean age of subjects included in each of the three
groups was similar. Smokers with emphysema had severe
airflow obstruction with a mean FEV1 of 40% predicted
(17%–64%) and a mean ratio FEV1/FVC of 45% (32%–
64%) whereas normal smokers and non-smokers had
normal lung function. Diffusion (DLCO) was reduced in
smokers with emphysema with a mean of 53% (30%–
81%) of predicted value. Smokers with emphysema had a
more important smoking history (70 pack-years, range
39–113) than normal smokers (43 pack-years, 16–65)
and a lower body mass index (BMI) than normal smokers
and non-smokers. According to the GOLD index for
COPD [1], two emphysematous smokers were classified
as GOLD stage II, five as GOLD stage III, and two as
GOLD stage IV.
Serum IL-6, TNF, and CRP
IL-6 was significantly higher in smokers with emphysema
than in the other two groups (Figure 2A) while TNF values
were similar in all groups (Figure 2B), and CRP tended to
be higher in smokers with or without emphysema
(ANOVA, p = 0.077) (Figure 2C). Even if this difference
between smokers with or without emphysema and non-
smokers did not reach statistical level, a mean CRP level
above 3 mg/L is considered to be consistent with the pres-
ence of low-grade systemic inflammation in emphysema-
tous and normal smokers [18].
Distribution of peripheral blood inflammatory cells
There were no significant differences in the total white cell
count and in the absolute number of monocytes and neu-
trophils between each group (Figure 3A). All subjects had
normal lymphocytes counts although the absolute
number of lymphocytes was significantly higher in
emphysematous smokers than in normal non-smokers,
and it tended to be higher in normal smokers than in nor-
mal non-smokers. Flow cytometry analyses of the CD4/
CD8 ratios (Figure 3B) did not show any difference
between the three groups.Respiratory Research 2007, 8:62 http://respiratory-research.com/content/8/1/62
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Perforin, granzyme B, and FasL protein expression in 
peripheral lymphocyte subsets
PBMCs were analyzed by flow cytometry to look at the
percentage of CD56+, CD4+, CD8+, and CD3+ cells that
express perforin and granzyme B protein (Figure 4), and
no difference was observed between the three groups. Fur-
ther analyses of perforin and granzyme B protein expres-
sion on CD8+ cells following CD16+ cells depletion also
did not show any differences (data not shown). The mean
fluorescence of perforin or granzyme B expressing cells
was not significantly different between the groups (data
not shown). Protein expression of FasL was not detected
by flow cytometry.
Perforin, granzyme B, and FasL mRNA expression in 
peripheral CD8+ T lymphocytes
Expression of perforin, granzyme B, and FasL mRNA was
assessed on CD8+/CD16- purified cells by real-time PCR
(Figure 5). A significant two fold decrease in perforin
mRNA was observed in emphysematous smokers when
compared to normal smokers and non-smokers. No sig-
nificant differences were seen in granzyme B and FasL
mRNA levels between the groups.
Discussion
This study was designed to determine if, in the presence of
systemic inflammation, the expression of the cytotoxic
and activation markers, perforin, granzyme B, and FasL,
by peripheral CD8+ T lymphocytes was upregulated in
emphysema. We chose to focus on emphysema rather
than in other component of COPD such as chronic bron-
chitis because the alveolar degradation that occurs in
emphysema has been linked to CD8+ T lymphocytes acti-
vation [5] which is not the case in chronic bronchitis and
other types of small airway disease. Despite the presence
of low-grade systemic inflammation shown by elevated
serum IL-6 and CRP levels (> 3 mg/L) [18] (Figure 2) in
emphysematous smokers, the percentage of systemic
CD56+, CD4+, CD8+, and CD3+ cells expressing perforin
and granzyme B protein was not different between the
three groups.
Up to now, fundamental research on emphysema has
mainly focussed on the inflammatory reaction that occurs
in the lung. The number of CD8+ T lymphocytes have
been shown to be increased in the emphysematous lung
leading to a decrease in the CD4/CD8 ratio [4,5,7], and
possibly to the decline of FEV1 [4-7]. In addition, sputum
CD8+ cells overexpress perforin and have an increased
Table 1: Real-time PCR primers description
Gene GenBank accession 
number
Primer sequences Amplicon size Annealing 
temperature
18S rRNA NR_003286 F: 5'-TGCATGGCCGTTCTTAGTTG-3' 76 bp 57°C
R: 5'-AGTTAGCATGCCAGAGTCTCGTT-3'
Perforin A26435 F: 5'-CGCCTACCTCAGGCTTATCTC-3' 155 bp 58°C
R: 5'-CCTCGACAGTCAGGCAGTC-3'
Granzyme B NM_004131 F: 5'-TGGGGGACCCAGAGATTAAAA-3' 100 bp 55°C
R: 5'-TTTCGTCCATAGGAGACAATGC-3'
FasL AF288573 F: 5'-TCAATGAAACTGGGCTGTACTTT-3' 101 bp 58°C
R: 5'-AGAGTTCCTCATGTAGACCTTGT-3'
Table 2: Subjects characteristics
Variables Normal non-smokers n = 10 Normal smokers n = 10 Emphysematous smokers n = 9
Age, yr 62 ± 2 58 ± 1 60 ± 1
Gender, F/M 3/7 2/8 2/7
FEV1, % predicted 112.2 ± 4.6 111.1 ± 4.1 39.6 ± 5.0*
FEV1/FVC 95.6 ± 1.8 94.0 ± 5.8 44.6 ± 3.5*
GOLD stage I/II/III/IV - - 0/2/5/2
DLCO, % predicted - - 53.4 ± 17.3
Smoking history, pack-years - 43 ± 4 70 ± 8*
BMI (kg/m2) 26.5 ± 1.1 27.0 ± 1.6 22.2 ± 0.6*
Presence of emphysema**, 
subjects
--9
* Significantly different from normal smokers and non-smokers (p < 0.05)
** Confirmed by CT scanningRespiratory Research 2007, 8:62 http://respiratory-research.com/content/8/1/62
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cytotoxic activity [8]. All of these data suggest that CD8+ T
lymphocytes are involved in the inflammation that occurs
in the emphysematous lung. Surprisingly, this increase in
the number of T lymphocytes in the lung of emphysema-
tous subjects does not seem to be reflected in peripheral
blood. Similar to other previously published studies
[19,20], we were able to demonstrate that peripheral
blood CD4/CD8 ratios (Figure 3B) is not decreased in
emphysema, illustrating some degree of discordance
between lung and peripheral blood. The expression of sev-
eral activation markers, such as CD25 [21], CD28 [20],
CD29 [20], CD45RO [20], and HLA-DR [19,21], by sys-
temic CD4+ and CD8+ T lymphocytes was also found to be
similar between COPD smokers, normal smokers, and
normal non-smokers. In an interesting study, Koch et al.
[22] reported that CD28 expression, which is an impor-
tant co-stimulatory molecule produced by systemic CD8+
T lymphocytes, was higher in smokers with or without
COPD as compared to normal non-smokers subjects.
These authors also showed that CD8+ T lymphocytes with
a cytotoxic effector phenotype (CD27-/CD45RA+) were
increased in the blood of smokers, with or without COPD
when compared to normal non-smokers. These observa-
tions suggest that cigarette smoking alone could not only
increase the expression of CD28 on systemic CD8+ T lym-
phocytes but also promote the presence of systemic CD8+
T lymphocytes exhibiting a cytotoxic effector phenotype.
In the current study, we analyzed perforin, granzyme B,
and FasL because such molecules are known to modulate
the cytotoxic power of CD8+ T lymphocytes [11]. Our
findings indicate that CD8+ T lymphocytes in the blood of
emphysematous smokers do not express more cytotoxic
molecules when compared to that of normal smokers and
to normal non-smokers. Hodge et al. [23] also looked at
perforin and granzyme B expression by peripheral blood
Blood inflammatory cells counts and CD4/CD8 ratio Figure 3
Blood inflammatory cells counts and CD4/CD8 ratio. A) Distribution of systemic inflammatory cells in the three groups 
obtained by automatized cell count. B) PBMC were isolated from each subjects, double labelled with fluorochrome-conjugated 
antibodies (CD3/CD4 and CD3/CD8), and analysed by flow cytometry. For each subject, CD4/CD8 ratio was obtained by 
dividing the %CD3+/CD4+ cells by the %CD3+/CD8+ cells. Columns represent mean ± SEM. *p = 0.02. Normal non-smokers 
(white), normal smokers (black), and emphysematous smokers (grey).
Serum IL-6, TNF, and C-reactive protein levels Figure 2
Serum IL-6, TNF, and C-reactive protein levels. For 
each subject, serum levels of A) IL-6 and B) TNF were quan-
tified by ELISA. C) Serum CRP levels were quantified by high 
sensitivity nephelometry. Columns represent mean ± SEM. 
*p = 0.002; **p = 0.0003. Normal non-smokers (white), nor-
mal smokers (black), and emphysematous smokers (grey).Respiratory Research 2007, 8:62 http://respiratory-research.com/content/8/1/62
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T lymphocytes, and unlike the findings of this study and
of others on the expression of activation markers by
peripheral T lymphocytes [19-21], they showed that the
percentage of peripheral CD3+ and CD8+ cells expressing
perforin and granzyme B is greater in COPD than in nor-
mal subjects. Their subjects recruitment was however only
based on FEV1 and FEV1/FVC values and their subjects
were not well-characterized in terms of COPD features
(emphysema, chronic bronchitis or small airways dis-
ease), systemic inflammation, and matched controls. It is
possible that with such bias, they recruited subjects with
an asthmatic component, which are known to have higher
levels of peripheral CD3+ and CD8+ cells expressing per-
forin [24].
Perforin, granzyme B, and FasL mRNA expression by isolated peripheral CD8+/CD16- cells Figure 5
Perforin, granzyme B, and FasL mRNA expression by isolated peripheral CD8+/CD16- cells. For each subject, 
total RNA was extracted from magnetically isolated CD8+/CD16- cells. mRNA expression of granzyme B, perforin, and FasL 
was assessed by real-time PCR, using 18S rRNA as housekeeping gene and compared using 2-∆∆Ct method. Columns represent 
mean ± SEM. *p = 0.02; **p = 0.05. Normal non-smokers (white), normal smokers (black), and emphysematous smokers 
(grey).
Perforin and granzyme B protein expression by peripheral CD56+, CD3+, CD4+, and CD8+ cells Figure 4
Perforin and granzyme B protein expression by peripheral CD56+, CD3+, CD4+, and CD8+ cells. PBMC were 
isolated from each subjects. They were first labelled with fluorochrome-conjugated anti-CD56, CD4, CD8, or CD3, permeabi-
lized, then labelled with fluorochrome-conjugated anti- A) granzyme B or B) perforin and analysed by flow cytometry. Columns 
represent mean ± SEM. Normal non-smokers (white), normal smokers (black), and emphysematous smokers (grey).Respiratory Research 2007, 8:62 http://respiratory-research.com/content/8/1/62
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We observed a decrease in the perforin mRNA levels in
CD8+/CD16- T lymphocytes of emphysematous smokers
compared to that of normal smokers (Figure 5), although
this difference was not reflected in the percentage of cell
expressing perforin (Figure 3B) or in the mean fluores-
cence. This discordance between mRNA and protein levels
may be explained by the fact that a two fold decrease in
the perforin mRNA is insufficient to influence the perforin
protein level in the cell, that some post-transcriptional
modifications are involved, or that perforin is contained
and accumulated in granules which may interfere with the
quantitative relation between mRNA and protein into the
cell.
The results of this study come from a highly selected pop-
ulation of emphysematous subjects who had some evi-
dence of systemic inflammation, as shown by high serum
IL-6 and CRP levels (Figure 2A–C). The absence of modu-
lation in the serum TNF levels (Figure 2B), also observed
by Debigaré et al. [25], could be explained by the fact that
TNF is mostly increased during periods of exacerbation of
the disease or during the cachexia process [26,27]. In our
study, emphysematous subjects did not have exacerbation
of their disease for at least three months prior to analysis
and all and had normal weight despite a significant lower
BMI when compared to the other groups. However, this
systemic inflammation in emphysematous smokers (Fig-
ure 2) was not associated with an increase in CD8+ T lym-
phocytes cytotoxic markers.
This difference between blood and lung cell populations
in emphysematous subjects was not only observed in the
lymphocyte population but also in monocytes/macro-
phage which are other important cells in the physiopa-
thology of emphysema [2]. These do not appear to be
increased or more activated in emphysematous subjects'
blood [28] despite the fact that alveolar macrophages are
markedly increased and highly activated in the paren-
chyma of emphysematous lungs, and that they release
much more proteases than in normal smokers and non-
smokers [29,30].
Our data suggest that activated CD8+ T lymphocytes in the
emphysematous lung may not be due to an increase in
markers of activation by peripheral blood CD8+ T lym-
phocytes and that a specific recruitment of inflammatory
cells by the lung due to specific chemotactic signals might
be a better hypothesis. Indeed, Saetta et al. [31] found an
increase of CXCR3+ cells, a Th1 receptor for IFN-γ-induced
chemokines, and IP-10, a CXCR3 ligand, in the COPD
lung. Grumelli et al. [32] also showed that lymphocytes
isolated from the lung of emphysematous subjects express
higher levels of CCR5, another Th1 receptor, and of
CXCR3 than those of normal subjects. Finally, Koch et al.
[22] found an increased CXCR3 expression by systemic
CD8+ T lymphocytes of COPD smokers compared to that
of normal smokers. All of this information suggests that
systemic T lymphocytes do not show higher levels of acti-
vation markers in the blood of emphysematous subjects,
but that they may be more sensitive to chemokines
induced by IFN-γ, thus facilitating their recruitment into
the lung.
One limitation of our study is the relative small number
of subjects in each group which may potentially mask a
significant difference, and power analyses determined
that 37 subjects in each group would be necessary to reach
an 80% power. Assuming that our subjects are represent-
ative of a larger population and even with significant dif-
ferences in peripheral T cells perforin and granzyme B
expression between normal smokers and emphysematous
smokers (means differences < 10%) (see Figure 4), this
difference would not be of important clinical relevance
and would still give results different from those of Hodge
et al. [23].
Conclusion
In summary, this study shows for the first time that,
despite evidence of low-grade systemic inflammation,
expression of perforin, granzyme B, and FasL by periph-
eral CD8+ T lymphocytes do not vary between emphyse-
matous smokers, smokers and non-smokers with normal
lung function. Our data is in concordance with other stud-
ies that have showed that the expression of activation
markers by systemic CD8+ T lymphocytes is not different
in emphysematous subjects than in normal subjects. Spe-
cific recruitment of activated cells by the lung may explain
the local cellular inflammatory phenotype of emphyse-
matous subjects. Further studies on T lymphocytes recruit-
ment by the emphysematous lung might be useful to
provide a better understanding of the physiopathology of
this complex disease.
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